Lack of Fas antagonism by Met in human fatty liver disease

Nature Medicine

Volumn 13, Issue 9, 2007, Pages 1078-1085

  Zou, Chunbin ^a   Ma, Jihong ^a   Wang, Xue ^a   Guo, Lida ^a   Zhu, Zhenqi ^a   Stoops, John ^a   Eaker, Amanda E ^a   Johnson, Carla J ^a   Strom, Stephen ^a   Michalopoulos, George K ^a   DeFrances, Marie C ^a   Zarnegar, Reza ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; FAS LIGAND; HISTIDYLHISTIDYLGLYCYLSERYLASPARTYLHISTIDYLGLUTAMYLARGINYLASPARAGINYL TYROSYLISOLEUCYLTYROSINE; HISTIDYLHISTIDYLISOLEUCYLPHENYLALANYLLEUCYLGLYCYLALANYLVALYLASPARAGINYL TYROSYLISOLEUCYLTYROSINE; HISTIDYLHISTIDYLISOLEUCYLTYROSYLLEUCYLGLYCYLALANYLVALYLASPARAGINYL TYROSYLISOLEUCYLTYROSINE; HISTIDYLSERYLSERYLTYROSYLLEUCYLGLYCYLALANYLVALYLPHENYLALANYL ASPARAGINYLLEUCYLTHREONINE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALPHA CHAIN; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY LIVER; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER DISEASE; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLLAGEN; FATTY LIVER; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; KINETICS; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR;

EID: 34948864852     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1625     Document Type: Article

References (35)

1. Canbay, A., Friedman, S. & Gores, G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39, 273-278 (2004).
2. Feldstein, A.E. et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437-443 (2003).
3. Feldstein, A.E. et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 39, 978-983 (2003).
4. Meagan, J. et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 39, 1230-1238 (2004).
5. Browning, J.D. & Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114, 147-152 (2004).
6. Diehl, A.M. et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54, 303-306 (2005).
7. Wang, X. et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor. Met. Mol. Cell 9, 411-421 (2002).
8. Huh, C.-G. et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. USA 101, 4477-4482 (2004).
9. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 4, 915-925 (2003).
10. Trusolino, L. & Comoglio, P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2, 289-300 (2002).
11. Gomez-Lechon, M.J. et al. A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact. 165, 106-616 (2007).
12. Nehra, V., Angulo, P., Buchman, A.L. & Lindor, K.D. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig. Dis. Sci. 46, 2347-2352 (2001).
13. Moriya, K. et al. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. Biochem. Biophys. Res. Commun. 281, 1207-1212 (2001).
14. Locksley, R.M., Killeen, N. & Lenardo, M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501 (2001).
15. Bodmer, J.L., Schneider, P. & Tshopp, J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27, 19-26 (2002).
16. Starling, G.C. et al. Identification of amino acid residues important for ligand binding to Fas. J. Exp. Med. 185, 1487-1492 (1997).
17. Connolly, K. et al. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J. Pharmacol. Exp. Ther. 298, 25-33 (2001).
18. Hasegawa, A. et al. Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc. Natl. Acad. Sci. USA 101, 6599-6604 (2004).
19. Yin, X.M. & Ding, W.X. Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr. Mol. Med. 3, 491-508 (2003).
20. Li, Z. et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37, 343-50 (2003).
21. Ding, X. et al. Exendin-4, a glucagon-like protein (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43, 173-181 (2006).
22. Anstee, Q.M. & Goldin, R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1-16 (2006).
23. Kirsch, R. et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18, 1272-1382 (2003).
24. Leon, A.L. & Rojkind, M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 33, 737-743 (1985).
25. Feldstein, A. & Gores, G.J. Steatohepatitis and apoptosis: therapeutic implications. Am. J. Gastroenterol. 99, 1718-1719 (2004).
26. Guicciardi, M.E. & Gores, G.J. Cheating death in the liver. Nat. Med. 10, 587-588 (2004).
27. Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347-351 (2003).
28. Zender, L. et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. USA 100, 7797-7802 (2003).
29. Farrell, G.C. & Larter, C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112 (2006).
30. Takeda, T. et al. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA 97, 5498-5503 (2000).
31. Michalopoulos, G.K. & DeFrances, M.C. Liver regeneration. Science 276, 60-66 (1997).
32. Taub, R. Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell Biol. 5, 836-847 (2004).
33. Ueki, T. et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 5, 226-230 (1999).
34. Corso, S., Comoglio, P.M. & Giordano, S. Cancer therapy: can the challenge be MET? Trends Mol. Med. 11, 284-292 (2005).
35. Nakamoto, Y. et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-Fas ligand antibody therapy. J. Exp. Med. 196, 1105-1111 (2002).